These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31479630)

  • 1. Use of Dolutegravir for Antiretroviral Therapy for Women of Childbearing Age.
    Atkin K; Scannell M; Nicholas PK
    J Obstet Gynecol Neonatal Nurs; 2019 Nov; 48(6):664-673. PubMed ID: 31479630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
    Money D; Lee T; O'Brien C; Brophy J; Bitnun A; Kakkar F; Boucoiran I; Alimenti A; Vaudry W; Singer J; Sauve LJ;
    BJOG; 2019 Oct; 126(11):1338-1345. PubMed ID: 31188522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
    Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
    N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir in pregnancy-effects on HIV-positive women and their infants.
    Bornhede R; Soeria-Atmadja S; Westling K; Pettersson K; Navér L
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):495-500. PubMed ID: 29396773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024.
    Navér L; Albert J; Carlander C; Gisslén M; Pettersson K; Soeria-Atmadja S; Sönnerborg A; Westling K; Yilmaz A; Pettersson K
    Infect Dis (Lond); 2024 Aug; 56(8):657-668. PubMed ID: 38805265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy.
    Nissim O; Lazenby GB
    J Midwifery Womens Health; 2021 May; 66(3):403-406. PubMed ID: 34166578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy.
    Grayhack C; Sheth A; Kirby O; Davis J; Sibliss K; Nkwihoreze H; Aaron E; Alleyne G; Laguerre R; Rana A; Badell M; Momplaisir F
    AIDS; 2018 Sep; 32(14):2017-2021. PubMed ID: 29944472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir becomes first choice for HIV.
    Rahimi S
    Lancet Infect Dis; 2019 Sep; 19(9):937-938. PubMed ID: 31478520
    [No Abstract]   [Full Text] [Related]  

  • 14. Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries - data from the ECEE Network Group.
    Gokengin D; Aho I; Sarıgül Yıldırım F; Bukovinova P; Siwak E; Papadopoulos A; Sedlacek D; Kowalska J
    Ginekol Pol; 2019; 90(7):411-415. PubMed ID: 31392711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Might dolutegravir be part of a functional cure for HIV?
    Wainberg MA; Han YS; Mesplède T
    Can J Microbiol; 2016 May; 62(5):375-82. PubMed ID: 27031127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
    Laker EAO; Arinaitwe A; Owarwo N; Onzia A; Nasasira B; Wailagala A; Kalule I; Anguzu G; Kiragga A; Seden K; Lwanga I; Castelnuovo B; Musomba R; Lamorde M
    Drug Saf; 2020 Nov; 43(11):1133-1140. PubMed ID: 32926356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
    Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
    J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
    Mofenson LM; Pozniak AL; Wambui J; Raizes E; Ciaranello A; Clayden P; Ehrenkranz P; Fakoya A; Hill A; Khoo S; Mahaka I; Modi S; Moore C; Phillips A; Siberry G; Sikwese K; Thorne C; Watts HD; Doherty M; Ford NP
    J Int AIDS Soc; 2019 Jul; 22(7):e25352. PubMed ID: 31298496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
    Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
    J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.